Table 3.

Primary outcomes, change from baseline, intention-to-treat

	Placebo (n = 16)			Fluvoxamine (n = 17)			P-value
	Day 14	Day 42	Day 70	Day 14	Day 42	Day 70	Day 14	Day 42	Day 70
VAS Fatigue	-1.3	-0.6	-0.55	-0.3	-0.4	-0.35	0.31	0.51	0.51
FFSS
Physical Domain	-2.0	-3.5	-4.0	0	-2.5	0	0.31	0.40	0.12
Cognitive Domain	-1.5	1.0	0	-1.0	-1.0	0	0.69	0.85	0.60
Social Domain	-3.0	-3.5	-2.0	-3.0	-4.0	-1.5	0.66	0.93	0.93
MFI
General Fatigue	-2.0	0	0	0	0	-1.0	0.10	0.62	0.87
Physical Fatigue	0	0	0	0	1.0	1.0	0.92	0.73	0.44
Reduction Activity	0.5	-1.0	0	1.0	-0.5	1.0	0.20	0.56	0.13
Reduction Motivation	-1.0	0	-1.0	1.0	-0.5	1.0	0.08	0.94	0.71
Mental Fatigue	-1.0	-0.5	0	0	0	0	0.06	0.35	0.89

Results are expressed as median differences in scores compared to baseline.